Task: Answer Verification
Input (English): Question: Is eGFR-TKI effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation?
Answer: EGFR-TKIs showed similar efficacy in patients with EGFR mutation-positive adenocarcinoma in terms of RR, PFS, and OS irrespective of treatment timing. Although EGFR-TKIs are currently the treatment of choice of first-line treatment in patients with EGFR-positive tumors, the sequential treatment with EGFR-TKI could be a reasonable option when EGFR mutation status cannot be obtained in a short time.
Output (English): yes